Skip to main content

RET fusion-positive NSCLC

Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC

RET fusion-positive NSCLC: delivering targeted treatment

Stephen Liu leads Melina Marmarelis and Vivek Subbiah in a discussion on the care of patients with RET fusion-positive NSCLC in light of the ARROW trial of pralsetinib.

Recorded: Thursday, 9 December, 2021 

Please feedback

Thank you for watching, please take 2 minutes to complete our survey.

Meet the faculty

Faculty disclosures

Faculty disclosures

Vivek Subbiah

Trial investigator on the ARROW study.

Stephen Liu

Trial investigator on the ARROW study.

Melina Marmarelis

Consulting/Honoraria: Boehringer Ingelheim, Novocure, AstraZeneca, Janssen, Takeda, Blueprint Pharmaceuticals, Bristol Myers Squibb, Ikena.

Research: Eli Lilly, Trizell, Merck, AstraZeneca.

Stock: Gilead, Merck, Portola pharmaceuticals, Bluebird Biosciences, Novartis, janssen, Pfizer.

Other: Novartis (medical writing support).



Funding and disclaimer

Funding and disclaimer

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Image Credits

Attention: This content is intended for healthcare professionals only

In order to proceed please confirm whether you are a healthcare professional.

No, I am not a
healthcare professional
Yes, I am a
healthcare professional